Skip to main content
OpenTrials

Clinical trial condition

Recurrent Bladder Urothelial Carcinoma

Explore clinical trials studying Recurrent Bladder Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

7 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Bladder Urothelial Carcinoma trial results

Completed

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT02844816

Conditions
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, +1 more
Locations
  • Southern Cancer Center PC-Daphne Daphne, Alabama, United States
  • Southern Cancer Center PC-Mobile Mobile, Alabama, United States
  • Southern Cancer Center PC-Providence Mobile, Alabama, United States
  • Southern Cancer Center PC-Springhill Mobile, Alabama, United States
View all 272 locations
View Trial Details
Completed

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

NCT03513952

Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Carcinoma, +40 more
Locations
  • Kaiser Permanente-Riverside Riverside, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Straub Clinic and Hospital Honolulu, Hawaii, United States
  • University of Hawaii Cancer Center Honolulu, Hawaii, United States
View Trial Details
Active, Not Recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Locally Advanced Bladder Urothelial Carcinoma, +36 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Keck Medicine of USC Buena Park Buena Park, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details

Related conditions